Europe Colorectal Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Modality [Imaging Tests and Stool-Based Tests] and End User

The Europe colorectal cancer diagnostics market was valued at US$ 3,145.81 million in 2023 and is expected to reach US$ 4,703.52 million by 2028. It is estimated to register a CAGR of 8.4% from 2023 to 2028.

Increasing Prevalence of Colorectal Cancer Drives Europe Colorectal Cancer Diagnostics Market Growth

Colorectal cancer is a malignant tumor that develops in colonic or rectal tissues. As per the data provided by the European Cancer Information System, in EU-27 countries, colorectal cancer accounted for 12.7% of all new cancer diagnoses and 12.4% of total mortalities caused by the disease in 2020. Such a high prevalence makes it the second most frequently occurring cancer, after breast cancer, and the second leading cause of cancer-related deaths, after lung cancer. Surgery is the most common treatment for all stages of colon cancer. In ideal situations, if the cancer is diagnosed in the early stages, doctors can remove the tumor via surgical procedures. A colonoscopy is an important screening test for colorectal cancer diagnostics, and it has become a part of routine cancer screening. Thus, rising prevalence of colorectal cancer drives the growth of the Europe colorectal cancer diagnostics market .

Europe Colorectal Cancer Diagnostics Market Overview

The European colorectal cancer diagnostics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. In Germany, the colorectal cancer diagnostics market is expected to grow in the coming years due to the rising development in the field of cancer and increasing prevalence of cancer. The National Cancer Plan of the Federal Ministry of Health (Nationaler Krebsplan des Bundesministeriums für Gesundheit) paved the way for the law to develop the cancer detection and quality assurance clinical cancer Registration Act (Gesetz zur Weiterentwicklung der Krebsfrüherkennung und zur Qualitätssicherung durch klinische Krebsregister), which the German parliament approved in 2013. This law prescribes the implementation of organized and quality-assured colon cancer screening programs. In addition, the screening approach for colorectal cancer in the country offers both men and women at least five annual faecal immunochemical tests (FITs) at ages 50-54, followed by a first screening colonoscopy at 55 years in case all of the FITs were negative. On April 4, 2019, a colorectal screening program was organized on the national level, which requires men aged 50 years and women aged 55 years of age to undergo a colonoscopy because of the rise in colorectal cancer risk. The Federal Joint Committee (G-BA) adopted the directive on organized cancer screening programs (oKFE-RL). Colorectal cancer screening was the first organized program to be implemented after that, and starting from July 2019, insured people aged 50 years are regularly invited for screening by health insurance companies. Therefore, the growing prevalence of colorectal cancer and increasing government approaches toward colorectal cancer screening are among the factors driving the Europe colorectal cancer diagnostics market growth.

Europe Colorectal Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

Europe Colorectal Cancer Diagnostics Market Segmentation

The Europe colorectal cancer diagnostics market is segmented into modality, end user, and country.

Based on modality, the Europe colorectal cancer diagnostics market is bifurcated into imaging tests and stool-based tests. In 2023, the imaging tests segment held a larger share of the Europe colorectal cancer diagnostics market. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.

Based on end user, the Europe colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. In 2023, the hospitals segment held the largest share of the Europe colorectal cancer diagnostics market.

Based on country, the Europe colorectal cancer diagnostics market is segmented into France, Germany, the UK, Italy, Spain, and the Rest of Europe. In 2023, Germany accounted for the largest share of the Europe colorectal cancer diagnostics market.

Medtronic Plc, Illumina Inc, Epigenomics AG, Novigenix SA, F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Siemens Healthineers AG, Bruker Corp, and Eiken Chemical Co., Ltd. are the leading companies operating in the Europe colorectal cancer diagnostics market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe colorectal cancer diagnostics market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Europe colorectal cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the colorectal cancer diagnostics market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution